Overview

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Status:
Completed

Trial end date:
2004-04-01

Target enrollment:

Participant gender:

Summary

The specific aim of this study is to document the pharmacokinetics of DAT receptor occupancy of OROS and immediate release (IR) MPH using PET scanning with C-11 altropane as the ligand. We hypothesize that the time to maximal receptor occupancy and the degree of receptor occupancy of immediate release (IR) MPH will be shorter and greater (respectively) than with an equipotent dose of OROS MPH.

Phase:

Phase 4

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Treatments:

Dopamine
Methylphenidate